🇺🇸 FDA
Patent

US 10570183

Use of a small native peptide activator of SERCA pump for treatment of heart failure and other disorders characterized by cytosolic calcium overload

granted A61KA61K38/1709A61K45/06

Quick answer

US patent 10570183 (Use of a small native peptide activator of SERCA pump for treatment of heart failure and other disorders characterized by cytosolic calcium overload) held by The Board of Regents of the University of Texas System expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Feb 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K38/1709, A61K45/06, A61K48/0058